¼¼°èÀÇ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ½ÃÀå º¸°í¼­(2025³â)
Biomarker Testing Global Market Report 2025
»óǰÄÚµå : 1764260
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,253,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,039,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,824,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 12.5%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 316¾ï 3,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ ¼ºÀåÀÇ ¹è°æ¿¡´Â ¾Ï ÀÌ¿Ü Áúȯ¿¡¼­ ¹ÙÀÌ¿À¸¶Ä¿ Àû¿ë È®´ë, µ¿¹ÝÁø´Ü¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, Áø´Ü ÇÁ·Î¼¼½º¿¡ ´ëÇÑ ÀΰøÁö´É ÅëÇÕ ÁøÀü, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î °Ë»ç äÅà Ȯ´ë, ¿¹¹æ ÇコÄɾ ´ëÇÑ ÀÎ½Ä Á¦°í µîÀÌ ÀÖ½À´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ½ÃÄö½Ì ±â¼úÀÇ ¹ßÀü, ¸®Äûµå ¹ÙÀ̿ɽÿ¡¼­ ±â¼ú Çõ½ÅÀÇ ÁøÀü, ¸ÖƼÇ÷º½º ¹ÙÀÌ¿À¸¶Ä¿ Ç÷§ÆûÀÇ Áøº¸, ÇÁ·ÎÅ׿À¹Í½º ¹× ¸ÞŸº¼·Î¹Í½º¿¡¼­ÀÇ µ¹ÆÄ, ¿¬±¸°³¹ß ÅõÀÚ Áõ°¡ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù.

¾Ï ºÎ´ã Áõ°¡´Â ÇâÈÄ ¼ö³â°£ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾ÏÀº ºñÁ¤»óÀûÀÎ ¼¼Æ÷ÀÇ Á¦¾î ºÒ°¡´ÉÇÑ Áõ½Ä°ú È®»êÀ¸·Î Ư¡Áö¾îÁö´Â Áúȯ±ºÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ºÎ´ãÀÇ Áõ°¡´Â °Ç°­ÇÏÁö ¸øÇÑ ½Ä»ýȰ, Èí¿¬, ¿îµ¿ ºÎÁ·, °úµµÇÑ ¾ËÄÚ¿Ã ¼·Ãë µî ¶óÀÌÇÁ ½ºÅ¸Àϰú °ü·ÃµÈ À§Çè ÀÎÀÚ¿¡ Å©°Ô ±âÀÎÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç´Â Áúȯ ƯÀÌÀû ¸¶Ä¿ÀÇ Á¶±â Á¤È®ÇÑ µ¿Á¤À» °¡´ÉÇÏ°Ô ÇÔÀ¸·Î½á Áø´Ü Á¤È®µµ¸¦ Çâ»ó½ÃŰ°í ¾Ï ¹ß°ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¶ÇÇÑ °³º°È­µÈ Ä¡·á Àü·«À» ÃËÁøÇϰí ȯÀÚÀÇ È¸±Í¸¦ °³¼±ÇÏ¿© º¸´Ù È¿À²ÀûÀÎ ÇコÄÉ¾î °ü¸®¸¦ ½ÇÇöÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 7¿ù È£ÁÖ º¸°Çº¹Áö·¦Àº 2022³â È£ÁÖ¿¡¼­ 165,70°ÇÀÇ ¾ÏÀÌ Áø´ÜµÅ 2021³â 15¸¸ 6,781°Ç¿¡¼­ 3,789°ÇÀÌ Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. µû¶ó¼­ ¾ÏÀÇ ÀÌȯÀ² Áõ°¡°¡ ¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ½ÃÀå È®´ë¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿À¸¶Ä¿ °Ë»ç ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷Àº Áø´Ü Á¤¹Ðµµ¸¦ ³ôÀ̰í, Áúº´ÀÇ Á¶±â ¹ß°ßÀ» °¡´ÉÇÏ°Ô Çϸç, ¸ÂÃãÇü Ä¡·á Àü·«À» Áö¿øÇϱâ À§ÇØ ¸é¿ªÁ¶Á÷È­ÇÐ(IHC) ±â¼ú µîÀÇ ±â¼úÀûÀ¸·Î ¼±ÁøÀûÀÎ ¼Ö·ç¼Ç °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¸é¿ªÁ¶Á÷È­ÇÐ(IHC)Àº Ç×ü¸¦ ÀÌ¿ëÇÏ¿© Á¶Á÷ »ùÇà ÁßÀÇ Æ¯Á¤ ´Ü¹éÁúÀ» °ËÃâÇÏ´Â °Ë»ç ±â¼úÀ̸ç, Áúº´ÀÇ Áø´ÜÀ̳ª ¿¬±¸¿¡ ÇʼöÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿ÀÇ µ¿Á¤ ¹× °¡½ÃÈ­¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ¿¹¸¦ µé¸é, ¹Ì±¹À» °ÅÁ¡À¸·Î ÇÏ´Â ÀÇ·á °Ë»ç ȸ»ç Äù½ºÆ® ´ÙÀֱ̾׳뽺ƽ½º ÀÎÄÚÆÛ·¹ÀÌÆ¼µå´Â, 2023³â 7¿ù, AmeriPath »ç¾÷À» ÅëÇØ¼­ »õ·Î¿î Á¶Á÷ ±â¹ÝÀÇ Àü¸³¼±¾Ï ¹ÙÀÌ¿À ¸¶Ä¿ °Ë»ç¸¦ °³½ÃÇß½À´Ï´Ù. ÀÌ °Ë»ç´Â ÀÚü ¹ÙÀÌ¿À¸¶Ä¿ÀÎ EV1, EV2, EV3¸¦ Ȱ¿ëÇØ ÀÇ»çµéÀÌ º¸´Ù Á¤È®ÇÏ°Ô ÁøÇ༺ Àü¸³¼±¾ÏÀ» µ¿Á¤ ¹× ½Äº°ÇÒ ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á Áø´Ü Á¤È®µµ¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ °Ë»ç´Â Áø´ÜÀÇ Àϰü¼ºÀ» ³ôÀ̰í ÀûÀýÇÑ °³º°È­ Ä¡·á Àü·«À» À¯µµÇÔÀ¸·Î½á ÀÓ»ó»óÀÇ Áß¿äÇÑ ¿ä±¸¿¡ ºÎÀÀÇÏ´Â °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï ¹× °ü¼¼, Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Biomarker testing involves examining blood, tissue, or other bodily fluids to detect specific biological indicators that signify either normal or pathological conditions. This process is vital for disease diagnosis, monitoring disease progression, and creating personalized treatment strategies.

Biomarker testing includes several product types such as consumables, instruments, services, and more. Consumables refer to items that are used and depleted during procedures and must be replenished regularly, including medical supplies, food items, or office essentials. The primary technologies employed are polymerase chain reaction (PCR), next-generation sequencing (NGS), immunoassays, among others. It is widely used in fields such as oncology, cardiology, neurology, and infectious diseases, with key end-users including hospitals, diagnostic labs, research institutions, and other healthcare settings.

The biomarker testing market research report is one of a series of new reports from The Business Research Company that provides biomarker testing market statistics, including the biomarker testing industry global market size, regional shares, competitors with the biomarker testing market share, detailed biomarker testing market segments, market trends, and opportunities, and any further data you may need to thrive in the biomarker testing industry. These biomarker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biomarker testing market size has grown rapidly in recent years. It will grow from $17.51 billion in 2024 to $19.75 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth during the historic period can be attributed to the rising adoption of personalized medicine, the increased utilization of biomarkers in oncology, the growing prevalence of chronic illnesses, expanded research funding in the life sciences sector, and the heightened demand for early disease detection.

The biomarker testing market size is expected to see rapid growth in the next few years. It will grow to $31.63 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to the expanding application of biomarkers in non-oncology conditions, increasing investments in companion diagnostics, greater integration of artificial intelligence into diagnostic processes, the rising adoption of point-of-care testing, and growing awareness of preventive healthcare. Key trends expected during the forecast period include advancements in sequencing technologies, ongoing innovations in liquid biopsy, progress in multiplex biomarker platforms, breakthroughs in proteomics and metabolomics, and rising investments in research and development.

The rising cancer burden is expected to drive the growth of the biomarker testing market in the coming years. Cancer comprises a group of diseases marked by the uncontrolled growth and spread of abnormal cells. This increasing burden is largely attributed to lifestyle-related risk factors such as unhealthy diets, smoking, physical inactivity, and excessive alcohol consumption. Biomarker testing plays a vital role in cancer detection by enabling early and accurate identification of disease-specific markers, thereby improving diagnostic precision. It also facilitates personalized treatment strategies, resulting in improved patient outcomes and more efficient healthcare management. For instance, in July 2024, the Australian Institute of Health and Welfare reported that 160,570 cancer cases were diagnosed in Australia in 2022, an increase of 3,789 cases from 156,781 in 2021. Therefore, the growing incidence of cancer is contributing significantly to the expansion of the biomarker testing market.

Major companies operating in the biomarker testing market are focusing on developing technologically advanced solutions, such as immunohistochemistry (IHC) technology, to enhance diagnostic accuracy, enable early disease detection, and support personalized treatment strategies. Immunohistochemistry (IHC) is a laboratory technique that utilizes antibodies to detect specific proteins in tissue samples, enabling the identification and visualization of biomarkers critical for disease diagnosis and research. For example, in July 2023, Quest Diagnostics Incorporated, a U.S.-based medical laboratory company, launched a new tissue-based prostate cancer biomarker test through its AmeriPath business. This test leverages proprietary biomarkers EV1, EV2, and EV3 to improve diagnostic precision by helping physicians more accurately identify and distinguish aggressive prostate cancer types. It addresses a critical clinical need by enhancing grading consistency and guiding appropriate, individualized treatment strategies.

In August 2025, Quanterix Corp., a U.S.-based life sciences company, acquired Emission Inc. for approximately $70 million. This acquisition is aimed at expanding Quanterix's technology portfolio and market presence by incorporating Emission's advanced multiplex and multi-omic assay technologies. The integration is expected to strengthen Quanterix's position in the biomarker testing sector, enhance its diagnostic capabilities, and open new market opportunities. Emission Inc. is a U.S.-based biotechnology company specializing in multiplex and multi-omic assay solutions for biomarker testing.

Major players in the biomarker testing market are Roche Diagnostics International Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company, GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Hologic Inc., Charles River Laboratories International Inc., PerkinElmer Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Myriad Genetics Inc., Guardant Health Inc., Sino Biological Inc., Proteome Sciences plc

North America was the largest region in the biomarker testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biomarker testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the biomarker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biomarker testing market consists of revenues earned by entities by providing services such as clinical biomarker testing services, bioinformatics and data analysis services, sample collection and biobanking services, and companion diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The biomarker testing market includes sales of analytical instruments, imaging devices, lab-on-a-chip and microfluidic devices, and data acquisition and integration hardware. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biomarker Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biomarker testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for biomarker testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biomarker testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Biomarker Testing Market Characteristics

3. Biomarker Testing Market Trends And Strategies

4. Biomarker Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Biomarker Testing Growth Analysis And Strategic Analysis Framework

6. Biomarker Testing Market Segmentation

7. Biomarker Testing Market Regional And Country Analysis

8. Asia-Pacific Biomarker Testing Market

9. China Biomarker Testing Market

10. India Biomarker Testing Market

11. Japan Biomarker Testing Market

12. Australia Biomarker Testing Market

13. Indonesia Biomarker Testing Market

14. South Korea Biomarker Testing Market

15. Western Europe Biomarker Testing Market

16. UK Biomarker Testing Market

17. Germany Biomarker Testing Market

18. France Biomarker Testing Market

19. Italy Biomarker Testing Market

20. Spain Biomarker Testing Market

21. Eastern Europe Biomarker Testing Market

22. Russia Biomarker Testing Market

23. North America Biomarker Testing Market

24. USA Biomarker Testing Market

25. Canada Biomarker Testing Market

26. South America Biomarker Testing Market

27. Brazil Biomarker Testing Market

28. Middle East Biomarker Testing Market

29. Africa Biomarker Testing Market

30. Biomarker Testing Market Competitive Landscape And Company Profiles

31. Biomarker Testing Market Other Major And Innovative Companies

32. Global Biomarker Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biomarker Testing Market

34. Recent Developments In The Biomarker Testing Market

35. Biomarker Testing Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â